Category: biotech

.Novo Nordisk is continuing its own press in to genetic medicines, accepting to compensate NanoVation Therapies approximately $600 million to team up on up to

.Novo Nordisk has actually axed its once-monthly dual GLP-1/ GIP receptor agonist, ending (PDF) growth of a medication applicant that it singled out as an

.Novo Nordisk has actually lifted the top on a phase 1 trial of its own oral amylin and also GLP-1 receptor co-agonist, connecting the prospect

.Novartis has actually had some bad luck with bispecific antitoxins in the past, but evaluating by the pharma’s most up-to-date deal it still believes the

.Do not stop Monte Rosa Rehabs currently. The Boston-based biotech is actually having a ball after signing a deal with Novartis ad valorem $150 thousand

.Novartis is opening a brand-new outpost in its cooperation along with Voyager Rehabs, paying for $15 thousand to use up its choice on an unfamiliar

.Noema Pharma has acquired a phase 2a gain for its Tourette disorder drug applicant, reporting hits on the main and also key secondary endpoints in

.Bayer put on hold the phase 3 trial for its factor XIa prevention asundexian behind time last year after the medicine showed “substandard efficacy” at

.Cell treatment biotech Endurance Bio has actually unveiled along with $17.2 thousand and also a mission of targeting invulnerable health conditions by flexing and also

.Neurocrine Biosciences’ schizophrenia course pivot has actually failed. The biotech was unable to replicate the knowledge signal it viewed in an earlier midphase study, urging